EVAH Corp

EVAH Corp, standing for Evolution in Animal Health, is a Quebec-based biotechnology company targeting the global animal health market with solutions designed to enhance food sustainability and security. Founded in 2020 by Michel Fortin, who serves as President and CEO, the company operates as a business and intellectual property platform. Fortin brings over 15 years of experience from his previous role as CEO of Prevtec Microbia, another Canadian animal health biotech firm. The management team that proved successful at Prevtec Microbia has been largely reassembled at EVAH.

The company's business model is centered on acquiring, developing, and de-risking promising animal health technologies to a pre-commercial stage. This strategy was notably demonstrated in May 2021, when EVAH acquired the development rights for four technologies from Elanco Animal Health. This portfolio includes vaccines and feed additives aimed at preventing bacterial diseases and improving growth performance in swine, poultry, and salmon. The company’s clients are primarily large-scale agri-food producers and integrators within the livestock and aquaculture sectors.

EVAH addresses the critical need for alternatives to antibiotics in food production, a response to the growing threat of antimicrobial resistance. Its product pipeline features a parasiticide for salmon, a vaccine to protect swine from a serious disease, and a broad-spectrum avian vaccine against E. coli. In April 2025, the company secured a U.S. patent for its in-feed sea lice treatment for farmed Atlantic salmon. The company's revenue is generated through strategic partnerships and the eventual commercialization of its developed technologies. Significant milestones include raising $20 million in a Series A round in 2021 and an additional $8.5 million in a Series B round in March 2023, bringing total funding to $28.5 million since its inception. In May 2024, EVAH opened new laboratories in Laval's biotechnology hub to advance its research and development projects toward commercialization.

Keywords: animal health biotechnology, food sustainability, antibiotic alternatives, animal vaccines, aquaculture health, swine health, poultry health, agri-food innovation, Michel Fortin, Elanco partnership, antimicrobial resistance solutions, food animal production, parasiticide, bacterial disease prevention, microbiome solutions, medicated feed, livestock technology, food supply chain resilience, One Health approach, pre-commercial biotech development